Apoptosis in cancer: Cause and cure

BioEssays

Volumn 22, Issue 11, 2000, Pages 1007-1017

  Kaufmann, Scott H ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CASPASE; INHIBITOR OF APOPTOSIS PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; TNFRSF10A PROTEIN, HUMAN; TNFRSF10B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL; APOPTOSIS; CELL CULTURE; ENZYME ACTIVATION; HUMAN; METABOLISM; NEOPLASM; REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR CELLS, CULTURED;

EID: 0033773114     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.0.CO;2-4     Document Type: Review

References (91)

1. Bcl-2 Gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
2. Induction of apoptosis in fibroblasts by c-Myc protein
3. Cooperative interaction between c-myc and bcl-2 proto-oncogenes
4. Insights from Bcl-2 and Myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation
5. Inhibition of apoptosis during development of colorectal cancer
6. Death substrates come alive
7. Mammalian caspases: Structure, activation, substrates and functions during apoptosis
8. Biochemical pathways of caspase activation during apoptosis
9. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
10. A caspase-actived DNase that degrades DNA during apoptosis, and its inhibitor ICAD
11. Apoptosis signaling by death receptors
12. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis
13. Apoptosis control by death and decoy receptors
14. Procaspase-3 is a major physiologic target of caspase-8
15. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway
16. Induction of apoptosis by cancer chemotherapy
17. Caspase-9 and APAF-1 form an active holoenzyme
18. ICE family proteases: Mediators of all apoptotic cell death?
19. Bcl-2 family proteins Oncogene
20. BCL-2 family members and the mitochondria in apoptosis
21. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC
22. Defective TNF-α-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases
23. STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs
24. PTEN: A tumour suppressor that functions as a phospholipid phosphatase
25. Mechanisms and consequences of activation of protein kinase B/Akt
26. Akt/protein kinase B inhibits cell death by preventing the release of cytochrome C from mitochondria
27. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation
28. The bile acid taurochenodeoxy-cholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade
29. IAP family proteins - Suppressors of apoptosis
30. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli
31. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
32. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
33. Overexpression of M68/ DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster
34. Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma
35. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
36. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
37. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progressing factors
38. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
39. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death
40. Involvement of FADD and caspase-8 signaling in detachment-induced apoptosis
41. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition
42. Mitochondrial permeability transition is altered in early stages of carcinogenesis of 2-acetylaminofluorene
43. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
44. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer
45. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers
46. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas
47. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6 associated with mucosa-associated lymphoid tissue lymphomas
48. Cellular survival: A play in three Akts
49. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas
50. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas
51. Growth factor synthesis and human breast cancer progression
52. The role of the IGF-I receptor in the growth and transformation of mammalian cells
53. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood
54. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor
55. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer
56. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway
57. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and - Independent pathways: Roles for phosphatidylinositol 3-kinase and Raf
58. Ras Signalling and apoptosis
59. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate
60. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function
61. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC
62. Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity
63. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma
64. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
65. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics
66. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations
67. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation
68. PIK3CA is implicated as an oncogene in ovarian cancer
69. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein Kkinase B
70. Phosphorylated forms of activated caspases are present in cytosol from HL-60 cells during etoposide-induced apoptosis
71. Regulation of cell death protease caspase-9 by phosphorylation
72. Caspase phosphorylation, cell death and species variability
73. Chronic infections and inflammatory processes as cancer risk factors: Possible role of nitric oxide in carcinogenesis
74. The role of nitric oxide (NO.) in the carcinogenic process
75. Tumor necrosis factor for the treatment of malignancies
76. Clinical applications of TNF-alpha in cancer
77. Lethal effect of the anti-Fas antibody in mice
78. Safety and antitumor activity of recombinant soluble Apo2 ligand
79. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
80. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
81. Antisense therapy of hematologic malignancies
82. PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection
83. Anti-cancer activity of targeted pro-apoptotic peptides
84. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
85. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis
86. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting
87. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: Protection is correlated with up regulation of Bcl-xL
88. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
89. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148
90. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted for chronic myelogenous leukemia
91. Activity of an Abl specific tyrosine kinase inhibitor in patients with Bcl-Abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis